BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Fig S5. Lack of association between TMB and clinical benefit among melanoma patients treated with Ipilimumab or Ipilimumab in combination with Nivolumab after progression on PD-1 monotherapy.